International Conference on Malignant Lymphoma | Conference

BGB-3111 Plus Obinutuzumab Effective in CLL and Follicular Lymphoma

June 17th 2017

Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.

BGB-3111 Induces Robust Response in Waldenstrom Macroglobulinemia

June 16th 2017

BGB-3111, a highly specific BTK inhibitor, is active in patients with Waldenström macroglobulinemia, according to an interim analysis from an ongoing phase I trial.

Avelumab Active in Hodgkin Lymphoma

June 16th 2017

Avelumab (Bavencio) demonstrated clinical activity and an acceptable safety and tolerability profile in heavily pretreated patients with classical Hodgkin lymphoma.

Dr. Schmitt on a Novel Treatment Approach to Hodgkin Lymphoma

June 16th 2017

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Dr. Berinstein on Combination Treatments for High-Risk and Recurrent Follicular Lymphoma

June 16th 2017

Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

Tazemetostat Active in Follicular Lymphoma, DLBCL

June 16th 2017

Tazemetostat (EPZ-6438) demonstrated strong clinical activity in patients with advanced EZH2-mutated follicular lymphoma, and was also active in patients with diffuse large B-cell lymphoma.

Expert Discusses Latest Nivolumab Data in Hodgkin Lymphoma

June 15th 2017

High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.

Pembrolizumab Active in Relapsed Mediastinal Large B-Cell Lymphoma

June 15th 2017

Pembrolizumab (Keytruda) demonstrated antitumor activity in the majority of patients with recurrent/refractory primary mediastinal large B-cell lymphoma.

Dr. Nastoupil on Pembrolizumab Plus Rituximab in Relapsed Follicular Lymphoma

June 15th 2017

Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Neelapu on Axi-Cel in the ZUMA-1 Trial for Refractory Aggressive Non-Hodgkin Lymphoma

June 15th 2017

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma.

Expert Discusses Ibrutinib/Venetoclax Combo in MCL

June 15th 2017

Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.

Axicabtagene Ciloleucel NHL Data Presented as FDA Weighs Approval

June 15th 2017

Patients with refractory aggressive non-Hodgkin lymphoma lacking curative treatment options demonstrated high response rates and durable responses plus a manageable safety profile following treatment with axicabtagene ciloleucel.

Tisagenlecleucel-T Highly Active, With Durable Responses in DLBCL

June 14th 2017

Tisagenlecleucel-T (CTL019) met its primary endpoint for best objective response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Kahl on ADCT-402 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 14th 2017

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

Dr. Tam on the Combination of Ibrutinib Plus Venetoclax in Mantle Cell Lymphoma

June 14th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Martin Barrett on Intravenous Versus Subcutaneous Rituximab

June 20th 2015

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

CAR-Modified T-Cell Therapy Shows Durable Response in Non-Hodgkin Lymphoma

June 20th 2015

Infusions of CTL019 achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive non-Hodgkin lymphoma.

Venetoclax Combination Shows Antitumor Activity in Advanced Myeloma

June 20th 2015

A three-drug combination comprising the novel Bcl-2 inhibitor venetoclax, bortezomib, and dexamethasone demonstrated a clinical benefit in heavily pretreated patients with relapsed/refractory multiple myeloma.

Lenalidomide Highly Effective in Early Phase CNS Lymphoma Study

June 20th 2015

Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.

Dr. Atanasio on Ibrutinib and Obinuzutumab Combination in CLL/SLL

June 20th 2015

Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naÃ¯ve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).